文献速递血脂与心血管预防冠心病心律失常

心血管代谢临床试验中死亡原因不明的频率、地区差异与预测因素:9项试验9259例死亡的汇总分析

Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials.
PubMed 文献 · Circulation · 2019-01-01

死因不明比例随治疗领域、入组地区和论文发表年份变化;急性冠脉综合征或房颤试验、入组至死亡时间更长、发表年份更近、北美入组、女性及高龄与死因不明可能性更高。

要点

  • 9项试验中15.6%的中心裁定死亡为死因不明,远非罕见。
  • 急性冠脉综合征或房颤试验、北美入组者死因不明比例更高。
  • 该比例可作为试验质量评估基线,提示需改进死因裁定流程。

核心结论

  • 9项长期随访的心血管代谢临床试验中约16%的死亡被中心裁定为死因不明,为试验质量评估提供基线并提示可减少此类死亡。

主要发现

  • 9259例死亡中5012例(54.1%)为心血管原因,2800例(30.2%)为非心血管原因,1447例(15.6%)为死因不明。
  • 死因不明比例随试验治疗领域、入组地区和论文发表年份存在差异。
  • 多变量分析显示急性冠脉综合征或房颤试验(对比动脉粥样硬化性血管病或糖尿病/糖尿病前期)、入组至死亡时间更长、论文发表年份更近、北美入组(对比西欧)、女性及高龄与死因不明可能性更高。

临床怎么用

  • 阅读心血管代谢试验结果时应关注死因不明比例,评估复合终点中心血管死亡数据的可靠性。
  • 试验设计可针对高危人群(如急性冠脉综合征、房颤、高龄、女性)加强死因信息收集与裁定流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Modern cardiometabolic clinical trials often include cardiovascular death as a component of a composite primary outcome, requiring central adjudication by a clinical events committee to classify cause of death. However, sometimes the cause of death cannot be determined from available data. The US Food and Drug Administration has indicated that this circumstance should occur only rarely, but its prevalence has not been formally assessed. METHODS: Data from 9 global clinical trials (2009-2017) with long-term follow-up and blinded, centrally adjudicated cause of death were used to calculate the proportion of deaths attributed to cardiovascular, noncardiovascular, or undetermined causes by therapeutic area (diabetes mellitus/pre-diabetes mellitus, stable atherosclerosis, atrial fibrillation, and acute coronary syndrome), region of patient enrollment, and year of trial manuscript publication. Patient- and trial-level variables associated with undetermined cause of death were identified using a logistic model. RESULTS: Across 127 049 enrolled participants from 9 trials, there were 9259 centrally adjudicated deaths: 5012 (54.1%) attributable to cardiovascular causes, 2800 (30.2%) attributable to noncardiovascular causes, and 1447 (15.6%) attributable to undetermined causes. There was variability in the proportion of deaths ascribed to undetermined causes by trial therapeutic area, region of enrollment, and year of trial manuscript publication. On multivariable analysis, acute coronary syndrome or atrial fibrillation trial (versus atherosclerotic vascular disease or diabetes mellitus/pre-diabetes mellitus), longer time from enrollment to death, more recent trial manuscript publication year, enrollment in North America (versus Western Europe), female sex, and older age were associated with greater likelihood of death of undetermined cause. CONCLUSIONS: In 9 cardiometabolic clinical trials with long-term follow-up, approximately 16% of deaths had undetermined causes. This provides a baseline for quality assessment of clinical trials and informs operational efforts to potentially reduce the frequency of undetermined deaths in future clinical research.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Fanaroff AC, Clare R, Pieper KS, et al. Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. Circulation. 2019. PMID: 30586739. doi:10.1161/CIRCULATIONAHA.118.037202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。